Medizinische Universität Graz - Research portal
Selected Publication:
Klein, W.
Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism)
Z Kardiol. 1992; 81(6):295-302
Web of Science
PubMed
- Authors Med Uni Graz:
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Meta-analysis of several large interventional trials in patients with mild to moderate hypertension has shown that coronary events are reduced to a much lesser extent than expected. One of the possible explanations for this are the metabolic side-effects of diuretics and betablockers used in these trials that may counteract their beneficial blood-pressure-lowering effect. Diuretics, especially thiazide, increase total cholesterol (+5%) and LDL-cholesterol (+10%), while betablockers decrease HDL-cholesterol (-5%) and increase triglycerides (+20%). Calcium antagonists and ACE-inhibitors do not affect lipids, and alpha-blockers have some beneficial effects. Regarding the carbohydrate metabolism, diuretics and betablockers decrease insulin sensitivity, increase plasma insulin, LDL-cholesterol, and triglycerides, and reduce HDL-cholesterol. Calcium channel blockers are neutral, while alpha-blockers and ACE-inhibitors improve glucose tolerance and reduce insulin resistance. To date, the clinical relevance of this side-effects is not known. Controlled, long-term trials in hypertensive patients with calcium channel blockers, ACE-inhibitors, and alpha-blockers are needed.
- Find related publications in this database (using NLM MeSH Indexing)
- Adrenergic beta-Antagonists - adverse effects
- Antihypertensive Agents - adverse effects
- Cholesterol - blood
- Coronary Disease - blood
- Diuretics - adverse effects
- Humans - adverse effects
- Hypertension - blood
- Lipids - blood
- Meta-Analysis - blood
- Risk Factors - blood
- Find related publications in this database (Keywords)
- Hypertension
- Antihypertensive Therapy
- Glucose Metabolism
- Lipid Metabolism